Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: Reports to VAERS

Vaccine

Volumn 31, Issue 51, 2013, Pages 6107-6112

  Halsey, Neal A ^a   Griffioen, Mari ^a   Dreskin, Stephen C ^b   Dekker, Cornelia L ^c   Wood, Robert ^d   Sharma, Devindra ^e   Jones, James F ^f   LaRussa, Philip S ^g   Garner, Jenny ^a   Berger, Melvin ^b   Proveaux, Tina ^a   Vellozzi, Claudia ^e   Broder, Karen ^h   Setse, Rosanna ⁱ   Pahud, Barbara ^j   Hrncir, David ^a   Choi, Howard ⁱ   Sparks, Robert ^a   Williams, Sarah Elizabeth ^a   Engler, Renata J ^a   Gidudu, Jane ^h   Baxter, Roger ^k   Klein, Nicola ^k   Edwards, Kathryn ^a   Cano, Maria ^h   Kelso, John M ^l   more..

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f KAISER PERMANENTE   (United States)

^g SCRIPPS CLINIC   (United States)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k Columbia University ^*  (United States)

^l CSL BEHRING   (United States)

more..

Author keywords

Allergic reactions; Anaphylaxis; H1N1 influenza vaccine; Hypersensitivity; Immunization; Influenza vaccine; Urticaria

Indexed keywords

ADRENALIN; DIPHENHYDRAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; INFLUENZA VACCINE; LIVE VACCINE; STEROID;

ABDOMINAL PAIN; ALLERGY TEST; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANXIETY DISORDER; ARTICLE; CONSCIOUSNESS DISORDER; COUGHING; CYANOSIS; DIARRHEA; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPNEA; EGG ALLERGY; ERYTHEMA; FAINTNESS; HOARSENESS; HUMAN; HYPOTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INJECTION SITE URTICARIA; NAUSEA; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY DISTRESS; RESPIRATORY TRACT ALLERGY; RHINORRHEA; SEX RATIO; SHOCK; SIDE EFFECT; SNEEZING; STRIDOR; SYSTEMATIC REVIEW; TACHYCARDIA; TACHYPNEA; THROAT TIGHTNESS; VOMITING; WHEEZING;

ALLERGIC REACTIONS; ANAPHYLAXIS; H1N1 INFLUENZA VACCINE; HYPERSENSITIVITY; IMMUNIZATION; INFLUENZA VACCINE; URTICARIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SEX FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84888433139     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.09.066     Document Type: Article

References (33)

1. Erlewyn-Lajeunesse M., Hunt L.P., Heath P.T., Erlewyn-Lajeunesse M., Hunt L.P., Heath P.T., et al. Anaphylaxis as an adverse event following immunisation in the UK and Ireland. Arch Dis Child 2012, 93(1):974-975.
2. Bohlke K., Davis R.L., Marcy S.M., Braun M.M., DeStefano F., Black S.B., et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003, 112(4):815-820.
3. Varricchio F., Iskander J., DeStefano F., Ball R., Pless R., Braun M.M., et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004, 23(4):287-294.
4. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Medical dictionary for regulatory activities (MedDRA). [accessed 29.08.13]. http://www.meddra.org/.
5. Food and Drug Administration 21 CFR Part 600.80. Postmarketing reporting of adverse experiences. Federal Register 1997, 62:52252-52253. http://www.gpo.gov/fdsys/granule/CFR-2009-title21-vol7/CFR-2009-title21-vol7-sec600-80/content-detail.html [accessed 29.08.13].
6. Williams S.E., Klein N.P., Halsey N., Dekker C.L., Baxter R.P., Marchant C.D., et al. Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009. Vaccine 2011, 29(40):6920-6927.
7. LaRussa P.S., Edwards K.M., Dekker C.L., Klein N.P., Halsey N.A., Marchant C., et al. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network. Pediatrics 2011, 127(Suppl. 1):S65-S73.
8. Rüggeberg J.U., Gold M.S., Bayas J.M., Blum M.D., Bonhoeffer J., Friedlander S., et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25(31):5675-5684.
9. CDC. National Health Interview Survey. Questionnaires, Datasets, and Related Documentation. [accessed 29.08.2013]. http://www.cdc.gov/nchs/nhis/nhis_questionnaires.htm.
10. Simons F.E. Anaphylaxis pathogenesis and treatment. Allergy 2011, 66(Suppl. 95):31-34.
11. Lieberman P., Nicklas R.A., Oppenheimer J., Kemp S.F., Lang D.M., Bernstein D.I., et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010, 126(3):477-480. Erratum in: J Allergy Clin Immunol 2010;126(6):1104.
12. Lee G.M., Greene S.K., Weintraub E.S., Baggs J., Kulldorff M., Fireman B.H., et al. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. Am J Prev Med 2011, 41(2):121-128.
13. Brown A.F., McKinnon D., Chu K. Emergency department anaphylaxis: a review of 142 patients in a single year. J Allergy Clin Immunol 2001, 108(5):861-866.
14. Poulos L.M., Waters A.M., Correll P.K., Loblay R.H., Marks G.B. Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, 1993-1994 to 2004-2005. J Allergy Clin Immunol 2007, 120(4):878-884.
15. Namork E., Fæste C.K., Stensby B.A., Egaas E., Løvik M. Severe allergic reactions to food in Norway: a ten year survey of cases reported to the food allergy register. Int J Environ Res Public Health 2011, 8(8):3144-3155.
16. Sole D., Ivancevich J.C., Borges M.S., Coelho M.A., Rosario N.A., Ardusso L.R., et al. Anaphylaxis in Latin America: a report of the online Latin American survey on anaphylaxis (OLASA). Clinics (Sao Paulo) 2011, 66(6):943-947.
17. Decker W.W., Campbell R.L., Manivannan V., Luke A., St Sauver J.L., Weaver A., et al. The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol 2008, 122(6):1161-1165.
18. Kurt E., Demir A.U., Cadirci O., Yildirim H., Pinar Eser T. Immediate-type drug hypersensitivity and associated factors in a general population. Allergol Immunopathol (Madr) 2011, 39(1):27-31.
19. Sheikh A., Alves B. Age, sex, geographical and socio-economic variations in admissions for anaphylaxis: analysis of four years of English hospital data. Clin Exp Allergy 2001, 31(10):1571-1576.
20. Weibel R.E., Stokes J., Buynak E.B., Hilleman M.R. Influence of age on clinical response to HPV-77 duck rubella vaccine. JAMA 1972, 222(7):805-807.
21. Swartz T.A., Klingberg W., Goldwasser R.A., Klingberg M.A., Goldblum N., Hilleman M.R. Clinical manifestations, according to age, among females given HPV-77 duck rubella vaccine. Am J Epidemiol 1971, 94(3):246-251.
22. Marano N., Plikaytis B.D., Martin S.W., Rose C., Semenova V.A., Martin S.K., et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 2008, 300(13):1532-1543. Erratum in: JAMA 2008;300(19):2252.
23. Arroabarren E., Lasa E.M., Olaciregui I., Sarasqueta C., Muñoz J.A., Pérez-Yarza E.G. Improving anaphylaxis management in a pediatric emergency department. Pediatr Allergy Immunol 2011, 22(7):708-714.
24. Cox L., Nelson H., Lockey R., Calabria C., Chacko T., Finegold I., et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011, 127(1 Suppl.):S1-S55.
25. American College of Allergy, Asthma, & Immunology Food allergy: a practice parameter. Ann Allergy Asthma Immunol 2006, 96(3 Suppl. 2):S1-S68.
26. Simons F.E.R. Pharmacologic treatment of anaphylaxis: can the evidence base be strengthened?. Curr Opin Allergy Clin Immunol 2010, 10:384-393.
27. Centers for Disease Control and Prevention (CDC) General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011, 60(2):1-61.
28. Wood R.A., Berger M., Dreskin S.C., Setse R., Engler R.J., Dekker C.L., et al. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics 2008, 122(3):e771-e777.
29. Kelso J.M. Administration of influenza vaccines to patients with egg allergy: update for the 2010-2011 season. J Allergy Clin Immunol 2010, 126(6):1302-1304.
30. Institute for Vaccine Safety. Allergens table. [updated 21.02.13; accessed 29.08.2013]. http://vaccinesafety.edu/components-Allergens.htm.
31. Coors E.A., Seybold H., Merk H.F., Mahler V. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol 2005, 95(6):593-599.
32. Centers for Disease Control and Prevention (CDC) Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011, 60(33):1128-1132.
33. Committee to Review Adverse Effects of Vaccines, Institute of Medicine Adverse effects of vaccines: evidence and causality 2012, The National Academies Press, Washington, DC, www.iom.edu/Reports/2011/Adverse-Effects-of-Vaccines-Evidence-and-Causality.aspx [accessed 29.08.2013].